A Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy

Area of Science:

• Neuroscience
• Clinical Psychology
• Neurology

Background:

• Progressive Supranuclear Palsy (PSP) is characterized by significant neuropsychological deficits, primarily impacting frontal lobe and subcortical brain regions.
• A dedicated scale for assessing cognitive and neuropsychiatric disability in PSP patients is currently lacking.
• This gap hinders comprehensive evaluation and management of the disease.

Purpose of the Study:

• To develop and validate a novel scale, the Short Cognitive and Neuropsychiatric (ShoCo) scale, for assessing cognitive and neuropsychiatric impairment in PSP.
• The scale aims to provide a reliable measure for clinical and research settings.

Main Methods:

• The Short Cognitive and Neuropsychiatric (ShoCo) scale was created with five items assessing bradyphrenia, apathy, aphasia, dysexecution, and disinhibition.
• A scoring system from 0 (no deficit) to 3 (severe deficit) per item was used, resulting in a total score range of 0–15.
• Data from 201 baseline and 71 follow-up patients were analyzed using cross-sectional and longitudinal approaches.

Main Results:

• The mean baseline ShoCo scale score was 5.9 ± 2.9.
• The scale demonstrated good correlation with established measures, such as the Montreal Cognitive Assessment (r = -0.535, P = 0.001).
• Significant annualized changes were observed in PSP-Richardson syndrome patients, indicating the scale's sensitivity to disease progression.

Conclusions:

• The Short Cognitive and Neuropsychiatric (ShoCo) scale is a promising and validated instrument for measuring specific neuropsychological disabilities in PSP patients.
• It is suitable for use in both clinical routine and research settings.
• The scale aids in the objective assessment of PSP-related cognitive and neuropsychiatric impairments.